|
Vaccine Comparison
CAdVa-Filoviruses (EbMarburg viruses) |
cAdVaxM(fus) |
Vaccine Information |
Vaccine Information |
- Vaccine Ontology ID: VO_0004645
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- GP from Musoke Marburgvirus
gene engineering:
- Type: Recombinant vector construction
- Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
- Detailed Gene Information: Click Here.
- GP from Marburg virus Ravn
gene engineering:
- Type: Recombinant vector construction
- Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
- Detailed Gene Information: Click Here.
- GP from Marburg virus Ci67
gene engineering:
- Type: Recombinant vector construction
- Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
- Detailed Gene Information: Click Here.
- Vector:
- Preparation: Three novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
- Immunization Route: Intramuscular injection (i.m.)
|
- Vaccine Ontology ID: VO_0004646
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- GP from Musoke Marburgvirus
gene engineering:
- Type: Recombinant vector construction
- Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
- Detailed Gene Information: Click Here.
- GP from Marburg virus Ravn
gene engineering:
- Type: Recombinant vector construction
- Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
- Detailed Gene Information: Click Here.
- GP from Marburg virus Ci67
gene engineering:
- Type: Recombinant vector construction
- Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
- Detailed Gene Information: Click Here.
- Vector:
- Preparation: Three novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
- Immunization Route: Intramuscular injection (i.m.)
|
References |
References |
Wang et al., 2006: Wang D, Schmaljohn AL, Raja NU, Trubey CM, Juompan LY, Luo M, Deitz SB, Yu H, Woraratanadharm J, Holman DH, Moore KM, Swain BM, Pratt WD, Dong JY. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses. Vaccine. 2006 Apr 5; 24(15); 2975-86. [PubMed: 16530297 ].
|
Wang et al., 2006: Wang D, Schmaljohn AL, Raja NU, Trubey CM, Juompan LY, Luo M, Deitz SB, Yu H, Woraratanadharm J, Holman DH, Moore KM, Swain BM, Pratt WD, Dong JY. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses. Vaccine. 2006 Apr 5; 24(15); 2975-86. [PubMed: 16530297 ].
|
|